Introduction and utilization of high priced HCV medicines across Europe; implications for the future

Frontiers in Pharmacology

Volumn 7, Issue JUL, 2016, Pages

  de Bruijn, Winnie ^a   Ibáñez, Cristina ^b   Frisk, Pia ^c   Bak Pedersen, Hanne ^d   Alkan, Ali ^e   Vella Bonanno, Patricia ^f   Brkicic, Ljiljana S ^g   Bucsics, Anna ^h   Dedet, Guillaume ⁱ   Eriksen, Jaran ^j   Fadare, Joseph O ^k   Fürst, Jurij ^l   Gallego, Gisselle ^m,n   Godói, Isabella P ^o   Guerra Júnior, Augusto A ^o   Gürsöz, Hakki ^e   Jan, Saira ^p,q   Jones, Jan ^f   Joppi, Roberta ^r   Kerman, Saim ^e   Laius, Ott ^s   Madzikwa, Newman ^t   Magnússon, Einar ^u   Maticic, Mojca ^v   Markovic Pekovic, Vanda ^w,x   Massele, Amos ^y   Ogunleye, Olayinka ^z,aa   O'Leary, Aisling ^ab   Piessnegger, Jutta ^f   Sermet, Catherine ^f   Simoens, Steven ^ac   Tiroyakgosi, Celda ^ad   Truter, Ilse ^ae   Thyberg, Magnus ^c   Tomekova, Kristina ^af   Wladysiuk, Magdalena ^ag   Vandoros, Sotiris ^ah   Vural, Elif H ^e   Zara, Corinne ^b   Godman, Brian ^j,ai   more..

^a UTRECHT UNIVERSITY   (Netherlands)

^b C Agy Hlth Technol Assess Res   (Spain)

^c STOCKHOLM COUNTY COUNCIL   (Sweden)

^d WHO REGIONAL OFFICE FOR EUROPE   (Denmark)

^e MINISTRY OF HEALTH   (Turkey)

^f Independent Pharmaceutical Consultant ^*  (France)

^g Croatian Health Insurance Agency   (Croatia)

^h UNIVERSITY OF VIENNA   (Austria)

ⁱ Research directorate studies evaluation and statistics (DREES)   (France)

^j KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^k EKITI STATE UNIVERSITY   (Nigeria)

^l Health Insurance Institute   (Slovenia)

^m UNIVERSITY OF NOTRE DAME   (Australia)

ⁿ UMEÅ UNIVERSITY   (Sweden)

^o FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^p RUTGERS UNIVERSITY   (United States)

^q HORIZON BLUE CROSS BLUE SHIELD OF NEW JERSEY   (United States)

^r Pharmaceutical Drug Department   (Italy)

^s State Agency of Medicines   (Estonia)

^t Ministry of Health and Child Care   (Zimbabwe)

^u Department of Epidemiology   (Iceland)

^v UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^w UNIVERSITY OF BANJA LUKA   (Bosnia and Herzegovina)

^x MINISTRY OF HEALTH AND SOCIAL WELFARE   (Bosnia and Herzegovina)

^y UNIVERSITY OF BOTSWANA   (Botswana)

^z LAGOS STATE UNIVERSITY TEACHING HOSPITAL   (Nigeria)

^aa LAGOS STATE UNIVERSITY   (Nigeria)

^ab National Centre for Pharmacoeconomics   (Ireland)

^ac UNIVERSITY OF LEUVEN   (Belgium)

^ad Department of HIV AIDS Prevention and Care   (Botswana)

^ae NELSON MANDELA METROPOLITAN UNIVERSITY   (South Africa)

^af Faculty of Natural Sciences   (Slovakia)

^ag HTA CONSULTING   (Poland)

^ah KING'S COLLEGE LONDON   (United Kingdom)

^ai UNIVERSITY OF STRATHCLYDE   (United Kingdom)

more..

Author keywords

Boceprevir; Cross national drug utilization study; Demand side measures; Hepatitis C; Introduction new medicines; Sofosbuvir; Telaprevir

Indexed keywords

BOCEPREVIR; PEGINTERFERON; RIBAVIRIN; TELAPREVIR;

ARTICLE; CROSS-SECTIONAL STUDY; DENMARK; DESCRIPTIVE RESEARCH; DRUG COST; DRUG UTILIZATION; EUROPE; HEALTH CARE COST; HUMAN; NETHERLANDS; PRESCRIPTION; SLOVENIA;

EID: 84981505057     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2016.00197     Document Type: Article

References (97)

1. Adamski, J., Godman, B., Ofierska-Sujkowska, G., Osiñska, B., Herholz, H., Wendykowska, K., et al. (2010). Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv. Res. 10:153. doi: 10.1186/1472-6963-10-153
2. Andrieux-Meyer, I., Cohn, J., de Araújo, E. S. A., and Hamid, S. S. (2015). Disparity in market prices for hepatitis C virus direct-acting drugs. Lancet Glob. Heal. 3, e676-e677. doi: 10.1016/S2214-109X(15)00156-4
3. Atun, R., Aydin, S., Chakraborty, S., Sümer, S., Aran, M., Gürol, I., et al. (2013). Universal health coverage in Turkey: enhancement of equity. Lancet 382, 65-99. doi: 10.1016/S0140-6736(13)61051-X
4. Aygen, B., Yildiz, O., Akhan, S., Çelen, M. K., Ural, O., Koruk, S. T., et al. (2015). Retreatment of Chronic Hepatitis C Infection with Telaprevir: preliminary results in Turkey. Balkan. Med. J. 32, 266-272. doi: 10.5152/balkanmedj.2015.15366
5. Barua, S., Greenwald, R., Grebely, J., Dore, G. J., Swan, T., and Taylor, L. E. (2015). Restrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann. Int. Med. 163, 215-223. doi: 10.7326/M15-0406
6. Björkhem-Bergman, L., Andersén-Karlsson, E., Laing, R., Diogene, E., Melien, O., Jirlow, M., et al. (2013). Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations. Eur. J. Clin. Pharmacol. 69(Suppl. 1), 73-78. doi: 10.1007/s00228-013-1497-5
7. Brennan, T., and Shrank, W. (2014). New expensive treatments for hepatitis C infection. JAMA 312, 593-594. doi: 10.1001/jama.2014.8897
8. Brincat, A. A., Deguara, M., Taliana, K., Rogers, M., and Pocock, J. (2013). The management of patients positive to hepatitis C virus antibody in Malta. Malta Med. J. 25, 72-77.
9. Cacace, M., Ettelt, S., Mays, N., and Nolte, E. (2013). Assessing quality in cross-country comparisons of health systems and policies: towards a set of generic quality criteria. Health Policy 112, 156-162. doi: 10.1016/j.healthpol.2013.03.020
10. Campbell, S. M., Godman, B., Diogene, E., Fürst, J., Gustafsson, L. L., MacBride-Stewart, S., et al. (2015). Quality indicators as a tool in improving the introduction of new medicines. Basic. Clin. Pharmacol. Toxicol. 116, 146-157. doi: 10.1111/bcpt.12295
11. Canary, L., Klevens, R., and Holmberg, S. (2015). Limited access to new hepatitis C virus treatment under state medicaid programs. Ann. Int. Med. 163, 226-228. doi: 10.7326/M15-0320
12. Cebolla, B., and Björnberg, A. (2012). Euro Hepatitis Index Report - Health Consumer Powerhouse. Available online at: http://www.healthpowerhouse.com/files/euro-hepatitis-index-2012/Report-Hepl-HCP-121104-2-w-Cover.pdf
13. Chen, E. Y., Sclair, S. N., Czul, F., Apica, B., Dubin, P., Martin, P., et al. (2013). A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir. Clin. Gastroenterol. Hepatol. 11, 1014-1020.e1-e2. doi: 10.1016/j.cgh.2013.03.032
14. Childs-Kean, L. M., and Hand, E. O. (2015). Simeprevir and sofosbuvir for treatment of Chronic Hepatitis C Infection. Clin. Ther. 37, 243-267. doi: 10.1016/j.clinthera.2014.12.012
15. Chou, R., Hartung, D., Rahman, B., Wasson, N., and Cottrell, E. B. (2014). Comparative effectiveness of antiviral treatment for Hepatitis C Virus infection in adults: a systematic review. Ann. Int. Med. 158, 114-123. doi: 10.7326/0003-4819-158-2-201301150-00576
16. Christensen, P. B., Clausen, M. R., Krarup, H., Laursen, A. L., Schlichting, P., and Weis, N. (2012). Treatment for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection - Danish national guidelines 2011. Dan. Med. J. 59, C4465.
17. Civaner, M. (2012). Sale strategies of pharmaceutical companies in a "pharmerging" country: the problems will not improve if the gaps remain. Health Policy 106, 225-232. doi: 10.1016/j.healthpol.2012.05.006
18. Cohen, J. P., and Felix, A. (2014). Are payers treating orphan drugs differently? J. Mark. Access Health Policy 2, 1-5. doi: 10.3402/jmahp.v2.23513
19. Coma, A., Zara, C., Godman, B., Agustí, A., Diogène, E., Wettermark, B., et al. (2009). Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction. Expert Rev. Pharmacoecon Outcomes Res. 9, 569-81. doi: 10.1586/erp.09.58
20. Cornberg, M., Razavi, H. A., Alberti, A., Bernasconi, E., Buti, M., Cooper, C., et al. (2011). A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int. 31(Suppl. 2), 30-60. doi: 10.1111/j.1478-3231.2011.02539.x
21. Cure, S., Guerra, I., Cammà, C., Craxì, A., and Carosi, G. (2015). Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy. J. Med. Econ. 18, 678-690. doi: 10.3111/13696998.2015.1040024
22. Deuffic-Burban, S., Deltenre, P., Buti, M., Stroffolini, T., Parkes, J., Mühlberger, N., et al. (2012). Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology 143, 974-985.e14. doi: 10.1053/j.gastro.2012.05.054
23. Dore, G. J., Ward, J., and Thursz, M. (2014). Hepatitis C disease burden and strategies to manage the burden. J. Viral Hepat. 21(Suppl. 1), 1-4. doi: 10.1111/jvh.12253
24. European Association for the Study of the Liver (2011). EASL clinical practice guidelines: management of Hepatitis C virus infection. J. Hepatol. 55, 245-264. doi: 10.1016/j.jhep.2011.02.023
25. European Association for the Study of the Liver (2014). EASL clinical practice guidelines: management of Hepatitis C Virus infection. J. Hepatol. 60, 392-420. doi: 10.1016/j.jhep.2013.11.003
26. European Centre for Desease Prevention Control (2010). Hepatitis B and C in the EU Neighbourhood: Prevalence. Burden: Burden of Disease and Screening Policies.
27. Experts in Chronic Myeloid Leukemia (2013). The price of drugs for chronic myeloid leukemia (CML) is a re fl ection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 121, 4439-4442. doi: 10.1182/blood-2013-03-490003
28. Ferrario, A., and Kanavos, P. (2013). Managed Entry Agreements for Pharmaceuticals: The European Experience. LSE. Available onlinje at: http://eprints.lse.ac.uk/50513/1/__Libfile_repository_Content_Ferrario%2C%20A_Ferrario_Managed_%20entry_%20agreements_2013_Ferrario_Managed_%20entry_%20agreements_2013.pdf (Accessed on: 15 Oct 2015).
29. Fojo, T., and Grady, C. (2009). How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J. Natl. Cancer Inst. 101, 1044-1048. doi: 10.1093/jnci/djp177
30. Ford, N., Swan, T., Beyer, P., Hirnschall, G., Easterbrook, P., and Wiktor, S. (2014). Simplification of antiviral hepatitis C virus therapy to support expanded access in resource-limited settings. J. Hepatol. 61(Suppl. 1). S132-S138. doi: 10.1016/j.jhep.2014.09.019
31. Fraser, I., Burger, J., Lubbe, M., Dranitsaris, G., Sonderup, M., and Stander, T. (2016). Cost-effectiveness modelling of sofosbuvir-containing regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa. Pharmacoeconomics 34, 403-417. doi: 10.1007/s40273-015-0356-x
32. Garuoliene, K., Alonderis, T., and Marcinkevic, M. (2010). Pharmaceutical policy and the effects of the economic crisis: Lithuania. Eurohealth 17, 1-4.
33. Garuoliene, K., Godman, B., Gulbinoviè, J., Wettermark, B., and Haycox, A. (2011). European countries with small populations can obtain low prices for drugs: Lithuania as a case history. Expert Rev Pharmacoecon Outcomes Res. 11, 343-349. doi: 10.1586/erp.11.24
34. Ghinea, N., Kerridge, I., and Lipworth, W. If we don't Talk About Value, Cancer Drugs Will Become Terminal for Health Systems [Internet]. Available online at: http://theconversation.com/if-we-dont-talk-about-value-cancer-drugs-will-become-terminal-for-health-systems-44072 (Accessed on Oct 2015).
35. Godman, B., Bishop, I., Finlayson, A. E., Campbell, S., Kwon, H.-Y., and Bennie, M. (2013b). Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries. Expert Rev Pharmacoecon Outcomes Res. 13, 469-482. doi: 10.1586/14737167.2013.820956
36. Godman, B., De Bruyn, K., Miranda, J., Raschi, E., Bennie, M., and Barbui, C. (2013a). Generic atypical antipsychotic drugs in Belgium: their influence and implications. J. Comp. Eff. Res. 2, 551-561. doi: 10.2217/cer.13.75
37. Godman, B., Malmström, R. E., Diogene, E., Gray, A., Jayathissa, S., and Timoney, A. (2015). Are new models needed to optimise the utilisation of new medicines to sustain healthcare systems? Expert Rev. Clin. Pharmacol. 8, 77-94. doi: 10.1586/17512433.2015.990380
38. Godman, B., Malmström, R. E., Diogene, E., Jayathissa, S., McTaggart, S., Cars, T., et al. (2014b). Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs. Front. Pharmacol. 5:109. doi: 10.3389/fphar.2014.00109
39. Godman, B., Petzold, M., Bennett, K., Bennie, M., Bucsics, A., Finlayson, A. E., et al. (2014a). Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications. BMC Med. 12:98. doi: 10.1186/1741-7015-12-98
40. Godman, B., Shrank, W., Andersen, M., Berg, C., Bishop, I., Burkhardt, T., et al. (2010a). Policies to enhance prescribing efficiency in europe: findings and future implications. Front. Pharmacol. 1:141. doi: 10.3389/fphar.2010.00141
41. Godman, B., Shrank, W., Andersen, M., Berg, C., Bishop, I., Burkhardt, T., et al. (2010b). Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. Expert Rev. Pharmacoecon. Outcomes Res. 10, 707-722. doi: 10.1586/erp.10.72
42. Gower, E., Estes, C. C., Hindman, S., Razavi-Shearer, K., and Razavi, H. (2014). Global epidemiology and genotype distribution of the hepatitis C virus. J. Hepatol. 61, S45-S57. doi: 10.1016/j.jhep.2014.07.027
43. Hatzakis, A., Wait, S., Bruix, J., Buti, M., Carballo, M., Cavaleri, M., et al. (2011). The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference. J. Viral Hepat. 18(Suppl. 1), 1-16. doi: 10.1111/j.1365-2893.2011.01499.x
44. Hesse, U., Godman, B., Petzold, M., Martin, A., and Malmström, R. (2013). Impact of delisting ARBs, apart from losartan, on ARB utilisation patterns in Denmark: implications for other countries. Appl. Heal Econ. Heal Policy 11, 677-685. doi: 10.1007/s40258-013-0059-4
45. Hézode, C., Fontaine, H., Dorival, C., Larrey, D., Zoulim, F., Canva, V., et al. (2013). Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J. Hepatol. 59, 434-441. doi: 10.1016/j.jhep.2013.04.035
46. Hézode, C., Fontaine, H., Dorival, C., Zoulim, F., Larrey, D., Canva, V., et al. (2014). Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 147, 132-142.e4. doi: 10.1053/j.gastro.2014.03.051
47. Hill, A., Khoo, S., Fortunak, J., Simmons, B., and Ford, N. (2014). Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries. Clin. Infect. Dis. 58, 928-936. doi: 10.1093/cid/ciu012
48. Hoebert, J. M., Mantel-Teeuwisse, A. K., van Dijk, L., Bijlsma, J. W. J., and Leufkens, H. G. M. (2012). Do rheumatoid arthritis patients have equal access to treatment with new medicines? Tumour necrosis factor-alpha inhibitors use in four European countries. Health Policy 104, 76-83. doi: 10.1016/j.healthpol.2011.10.011
49. Hofmann, W. P., Sarrazin, C., and Zeuzem, S. (2012). Current standards in the treatment of chronic hepatitis C. Dtsch. Arztebl. Int. 109, 352-358. doi: 10.3238/arztebl.2012.0352
50. Hope, V. D., Eramova, I., Capurro, D., and Donoghoe, M. C. (2014). Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association. Epidemiol. Infect. 142, 270-286. doi: 10.1017/S0950268813000940
51. Hughes-Wilson, W., Palma, A., Schuurman, A., and Simoens, S. (2012). Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Orphanet. J. Rare Dis. 7:74. doi: 10.1186/1750-1172-7-74
52. Iyengar, S., Tay-Teo, K., Vogler, S., Beyer, P., Wiktor, S., de Joncheere, K., et al. (2016). Prices, costs, and affordability of new medicines for Hepatitis C in 30 countries: an economic analysis. PLoS med. 13:e1002032. doi: 10.1371/journal.pmed.1002032
53. Jönsson, B., Ramsey, S., and Wilking, N. (2014). Cost effectiveness in practice and its effect on clinical outcomes. J. Cancer Policy 2, 12-21. doi: 10.1016/j.jcpo.2014.02.001
54. Kantarjian, H. M., Fojo, T., Mathisen, M., and Zwelling, L. A. (2013). Cancer drugs in the United States: Justum Pretium-the just price. J. Clin. Oncol. 31, 3600-3604. doi: 10.1200/JCO.2013.49.1845
55. Kohli, A., Shaffer, A., Sherman, A., and Kottilil, S. (2014). Treatment of Hepatitis C. JAMA. 312, 631. doi: 10.1001/jama.2014.7085
56. Lagging, M., Duberg, A.-S., Wejstål, R., Weiland, O., Lindh, M., Aleman, S., et al. (2012). Treatment of hepatitis C virus infection in adults and children: updated Swedish consensus recommendations. Scand. J. Infect. Dis. 44, 502-521. doi: 10.3109/00365548.2012.669045
57. Lemoine, M., and Asia, E. (2014). Hepatitis C, A Global Issue: access to care and new therapeutic and preventive approaches in resource-constrained areas. Semin. Liver Dis. 34, 89-97 doi: 10.1055/s-0034-1371082
58. Leroy, V., Serfaty, L., Bourlière, M., Bronowicki, J.-P., Delasalle, P., Pariente, A., et al. (2012). Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver. Liver Int. 32, 1477-14492. doi: 10.1111/j.1478-3231.2012.02856.x
59. Lo Re, V. III., Teal, V., Localio, A., Amorosa, V., Kaplan, D., and Gross, R. (2011). Relationship between adherence to hepatitis C virus therapy and virologic outcomes: a cohort study. Annals of internal medicine. Ann. Intern. Med. 155, 353-360. doi: 10.7326/0003-4819-155-6-201109200-00003
60. Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., et al. (2012). Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2095-2128. doi: 10.1016/S0140-6736(12)61728-0
61. Malmström, R. E., Godman, B. B., Diogene, E., Baumgärtel, C., Bennie, M., Bishop, I., et al. (2013). Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Front. Pharmacol. 4:39. doi: 10.3389/fphar.2013.00039
62. Manns, M. P., Pockros, P. J., Norkrans, G., Smith, C. I., Morgan, T. R., Häussinger, D., et al. (2013). Long-term clearance of hepatitis C virus following interferon a-2b or peginterferon a-2b, alone or in combination with ribavirin. J. Viral Hepat. 20, 524-529. doi: 10.1111/jvh.12074
63. Manzano-Robleda, M. C., Ornelas-arroyo, V., Barrientos-gutiérrez, T., Méndez-sánchez, N., Uribe, M., and Chávez-tapia, N. C. (2015). Boceprevir and telaprevir for chronic genotype 1 hepatitis C virus infection. A systematic review and meta-analysis. Ann. Hepatol. 14, 46-57.
64. Mathurin, P. (2013). HCV burden in Europe and the possible impact of current treatment. Dig. Liver Dis. 45, S314-S317. doi: 10.1016/j.dld.2013.07.009
65. Maticic, M. (2014). A national multidisciplinary healthcare network for treatment of hepatitis C in people who inject drugs in Slovenia. BMC Infect Dis. 14(Suppl 6):S6. doi: 10.1186/1471-2334-14-S6-S6
66. McGowan, C. E., Monis, A., Bacon, B. R., Mallolas, J., Goncales, F. L., Goulis, I., et al. (2013). A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care. Hepatology 57, 1325-1332. doi: 10.1002/hep.26246
67. McHutchison, J. G., Manns, M., Patel, K., Poynard, T., Lindsay, K. L., Trepo, C., et al. (2002). Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 123, 1061-1069. doi: 10.1053/gast.2002.35950
68. McHutchison, J., Stuart, C., Schiff, E., Shiffman, M., Lee, W., and Rustgi, V. (1998). Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. NEJM 339, 1485-1492. doi: 10.1056/NEJM199811193392101
69. Messina, J. P., Humphreys, I., Flaxman, A., Brown, A., Cooke, G. S., Pybus, O. G., et al. (2014). Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61, 77-87. doi: 10.1002/hep.27259
70. Messori, A. (2015a). Newest treatments for hepatitis C: how can we manage sustainability? Clin. Infect. Dis. 16, 1891-1892. doi: 10.1093/cid/civ667
71. Messori, A. (2015b). Value-based pricing is inadequate for both high budget-impact drugs and orphan drugs: exploring original methods to overcome this limitation by adjusting prices according to the number of potential patients. BMJ 351:h4988.
72. Mohd Hanafiah, K., Groeger, J., Flaxman, A. D., and Wiersma, S. T. (2013). Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57, 1333-1342. doi: 10.1002/hep.26141
73. Montazerhodjat, V., Weinstock, D. M., and Lo, A. W. (2016). Buying cures versus renting health: financing health care with consumer loans. Sci. Transl. Med. 8, 327ps6. doi: 10.1126/scitranslmed.aad6913
74. Moon, J. C., Godman, B., Petzold, M., Alvarez-Madrazo, S., Bennett, K., Bishop, I., et al. (2014). Different initiatives across Europe to enhance losartan utilization post generics: impact and implications. Front. Pharmacol. 5:219. doi: 10.3389/fphar.2014.00219
75. Nolte, E., and Corbett, J. International Variation in Drug Usage Variation: An Exploratory Analaysis of the "Causes" of Variation [Internet]. [cited 2015 Mar 8]. Available online at: http://www.rand.org/pubs/research_reports/RR899.html
76. Norton, A. (2015). Hepatitis C Drugs Will 'Strain Budgets' at Current Prices: Study - The New Therapies Have Remarkably High Cure Rates. Available online at: URL: http://consumer.healthday.com/infectious-disease-information-21/hepatitis-news-373/hepatitis-c-drugs-will-strain-budgets-at-current-prices-study-697479.html
77. Orlent, H., Deltenre, P., Francque, S., Laleman, W., Moreno, C., Bourgeois, S., et al. (2012). Update of the Belgian Association for the Study of the Liver guidelines for the treatment of chronic hepatitis C genotype 1 with protease inhibitors. Acta Gastroenterol. Belg. 75, 245-259.
78. Papastergiou, V., and Karatapanis, S. (2015). Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6. World J. Clin. Cases. 3, 210-220. doi: 10.12998/wjcc.v3.i3.210
79. Phelan, M., and Cook, C. (2014). A treatment revolution for those who can afford it? Hepatitis C treatment: new medications, profits and patients. BMC Infect Dis. 14(Suppl 6):S5. doi: 10.1186/1471-2334-14-S6-S5
80. Poynard, T., Marcellin, P., Lee, S. S., Niederau, C., Minuk, G. S., Ideo, G., et al. (1998). Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352, 1426-1432.
81. Putrik, P., Ramiro, S., Kvien, T. K., Sokka, T., Pavlova, M., Uhlig, T., et al. (2014). Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann. Rheum. Dis. 73, 198-206. doi: 10.1136/annrheumdis-2012-202603
82. Ramachandran, P., Fraser, A., Agarwal, K., Austin, A., Brown, A., Foster, G. R., et al. (2012). UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. Aliment. Pharmacol. Ther. 35, 647-662. doi: 10.1111/j.1365-2036.2012.04992.x
83. Rein, D. (2015). Reply to Messori. Clin. Infect. Dis. 61, 1892-1893. doi: 10.1093/cid/civ668
84. Schalm, S. W., Hansen, B. E., Chemello, L., Bellobuono, A., Brouwer, J. T., Weiland, O., et al. (1997). Meta-analysis of individual patient data from European centers. J. Hepatol. 26, 961-966. doi: 10.1016/S0168-8278(97)80103-1
85. Senior, M. (2014). Sovaldi makes blockbuster history, ignites drug pricing unrest. Nat. Biotechnol. 32, 501-502. doi: 10.1038/nbt0614-501
86. Simoens, S., Picavet, E., Dooms, M., Cassiman, D., and Morel, T. (2013). Cost-effectiveness assessment of orphan drugs: a scientific and political conundrum. Appl. Health Econ. Health Policy. 11, 1-3. doi: 10.1007/s40258-012-0004-y
87. Thein, H.-H., Yi, Q., Dore, G. J., and Krahn, M. D. (2008). Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 48, 418-431. doi: 10.1002/hep.22375
88. Trooskin, S. B., Reynolds, H., and Kostman, J. R. (2015). Access to costly new hepatitis C drugs: medicine, money, and advocacy. Clin. Infect. Dis. 61, 1825-1830. doi: 10.1093/cid/civ677
89. van de Ven, N., Fortunak, J., Simmons, B., Ford, N., Cooke, G. S., Khoo, S., et al. (2014). Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat Hepatitis C Virus. Hepatology 61, 1174-1182. doi: 10.1002/hep.27641
90. Vogler, S., Zimmermann, N., Habl, C., and Mazag, J. (2013). The role of discounts and loss leaders in medicine procurement in Austrian hospitals - a primary survey of official and actual medicine prices. Cost Effect. Resour. Alloc. 11:15. doi: 10.1186/1478-7547-11-15
91. Vonèina, L., Strizrep, T., Godman, B., Bennie, M., Bishop, I., Campbell, S., et al. (2011). Influence of demand-side measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for the future. Expert Rev. Pharmacoecon. Outcomes Res. 11, 469-479. doi: 10.1586/erp.11.42
92. Wedemeyer, H., Dore, G. J., and Ward, J. W. (2015). Estimates on HCV disease burden worldwide - filling the gaps. J. Viral Hepat. 22(Suppl. 1), 1-5. doi: 10.1111/jvh.12371
93. Westbrook, R. H., and Dusheiko, G. (2014). Natural history of hepatitis C. J. Hepatol. 61(1 Suppl.), S58-S68. doi: 10.1016/j.jhep.2014.07.012
94. Wettermark, B., Godman, B., Jacobsson, B., and Haaijer-Ruskamp, F. M. (2009). Soft regulations in pharmaceutical policy making: an overview of current approaches and their consequences. Appl. Health Econ. Health Policy 7, 137-147. doi: 10.1007/BF03256147
95. World Health Organisation (2012). The 10 Leading Causes of Death by Country Income Group. Available onlie at: http://www.who.int/mediacentre/factsheets/fs310/en/index1.html.
96. Yehia, B. R., Schranz, A. J., Umscheid, C. A., and Lo Re, V. (2014). The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. PLoS ONE 9:e101554. doi: 10.1371/journal.pone.0101554
97. Younossi, Z. M., Park, H., Saab, S., Ahmed, A., Dieterich, D., and Gordon, S. C. (2015). Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment. Pharmacol. Ther. 41, 544-563. doi: 10.1111/apt.13081